{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-059936","form_type":"8-K","ticker":"PLUR","cik":"0001158780","company_name":"Pluri Inc.","filed_at":"2022-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.097553+00:00","generated_at":"2026-06-23T06:37:53.631693+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pluri signs biologics API collaboration, cuts cash burn 30%, holds $56M cash","bullets":["New collaboration with European API manufacturer for liver/gastro drugs; revenue expected in coming months.","Annual cash burn reduced ~30% from $36M to ~$24M; $56M cash at June 30, 2022.","Plurinuva JV with Tnuva: first cultivated meat product in development; proof of concept this year, launch 2023.","Second tech collaboration after Tnuva; targets $366B biologics market, growing to $720B by 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-059936","json":"https://secwatch.observer/filing/0001213900-22-059936.json","markdown":"https://secwatch.observer/filing/0001213900-22-059936.md","text":"https://secwatch.observer/filing/0001213900-22-059936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158780/000121390022059936/0001213900-22-059936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158780/000121390022059936/ea166516-8k_pluriinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:37:53.631693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}